Next Generation Deep Sequencing to Evaluate Viral Tropism in HIV-1 Patients Exposed to Maraviroc...
-
Upload
edgar-glenn -
Category
Documents
-
view
212 -
download
0
Transcript of Next Generation Deep Sequencing to Evaluate Viral Tropism in HIV-1 Patients Exposed to Maraviroc...
Next Generation Deep Sequencing to Evaluate Viral Tropism in HIV-1 Patients Exposed to Maraviroc Add-On Therapy
for 8 Days
*Rachel A. McGovern, Art F.Y. Poon, Manuel Leal, Miguel Genebat, Ezequiel Ruiz-Mateos, P. Richard Harrigan
Poster #TUPDA0102
Background
• The Maraviroc Clinical Test (MCT) evaluates virological response following 8 days of exposure to MVC add-on therapy
• 27 MCT patients were followed longitudinally by 454 sequence analysis
• Sequences were interpreted by Geno2Phenocoreceptor algorithm (3.5 FPR cutoff); >2% X4 virus was considered non-R5
• Analyses were conducted to identify any association between the degree of viral suppression and g2p score
R5 X4Maraviroc
X
In those screened non-R5 by genotype MVC inhibited R5 virus, however the overall pVL remained fairly constant as non-R5 virus took over the population within 8 days.
B) Screened non-R5 by deep sequencingA) Screened R5 by deep sequencing
Maraviroc exposure in patients with non-R5 virus led to strong selection for virus with an extremely low FPR
In Summary patients with non-R5 virus, when exposed to short-term maraviroc add-on therapy, demonstrated a strong selection for X4 variants having extremely low g2P scores (0 ≤ FPR < 2) in as few as 8 days.
False Positive Rate Re
lativ
e Fi
tnes
s in
the
Pre
senc
e of
Mar
aviro
c
0.
0
0.2
0.
4 0
.6
0.8
1
.0
0 5 10 15 20
B)Screened non-R5 (3.4% X4)A)